High Mobility Group Box 1 (HMGB1)

HMGB1 is a protein normally found inside the nucleus of cells, where it helps organize DNA. When cells are injured or killed, as happens when asbestos fibers damage mesothelial cells lining the chest and abdomen, HMGB1 leaks out and acts as a powerful alarm signal that drives chronic inflammation. This sustained inflammation is now understood to be a key step linking asbestos exposure to the later development of mesothelioma.

Origin

The HMG protein family was first described in the 1970s by Ernest Johns and colleagues, named for the proteins' unusually fast ("high mobility") movement during gel electrophoresis. HMGB1's role as an extracellular danger signal was identified in the late 1990s by Kevin Tracey's group, and its specific role in asbestos-driven mesothelioma was demonstrated by Michele Carbone, Haining Yang, and colleagues beginning around 2010.

Significance in Asbestos Context

HMGB1 helps answer a question patients often ask: how can fibers inhaled decades ago cause cancer so much later? When asbestos fibers kill mesothelial cells through a specific process called programmed necrosis, those dying cells release HMGB1, which recruits immune cells and sustains inflammation for years. This chronic inflammatory environment promotes the genetic changes that eventually lead to mesothelioma. HMGB1 is also being studied as a blood and tissue biomarker. Elevated levels (particularly the hyper-acetylated form) have been found in asbestos-exposed individuals and mesothelioma patients, and may help distinguish mesothelioma from benign asbestos-related conditions. In legal cases, HMGB1 research is frequently cited by medical experts to explain the biological mechanism connecting a patient's past exposure to their current disease.

Example Sentence

The plaintiff's expert pathologist explained that HMGB1 released from asbestos-damaged mesothelial cells drove decades of chronic inflammation that ultimately produced the patient's pleural mesothelioma.

Related Terms

Chronic Inflammation, Mesothelioma, Programmed Cell Necrosis, Biomarker, BAP1, Mesothelial Cells

Notes

• If you have been diagnosed with mesothelioma or are being monitored after asbestos exposure, ask whether HMGB1 testing (serum levels) is available through a research protocol or specialized mesothelioma center; it is not yet a standard clinical test but is used in some academic programs.
• Ask your oncologist whether any open clinical trials are testing HMGB1-targeted therapies (such as aspirin, which can reduce HMGB1 activity, or specific HMGB1 inhibitors) for which you might qualify.
• For legal claims, preserve copies of any pathology reports, research-protocol results, or expert reports that reference HMGB1 or inflammation markers. These can support the scientific explanation of how your exposure caused your disease.
• HMGB1 is not specific to asbestos disease; elevated levels also occur in infection, trauma, and other cancers, so interpretation requires a physician familiar with your full history.